Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease

被引:119
作者
McEnaney, Patrick J. [1 ]
Parker, Christopher G. [1 ]
Zhang, Andrew X. [1 ]
Spiegel, David A. [1 ,2 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
关键词
RECEPTOR-TARGETED IMMUNOTHERAPY; PROTEIN-PROTEIN INTERACTIONS; LASTING ANTITUMOR IMMUNITY; GROWTH-FACTOR RECEPTOR; ALPHA-V INTEGRINS; FC-GAMMA-R; PLASMINOGEN-ACTIVATOR; MONOCLONAL-ANTIBODIES; BISPECIFIC ANTIBODIES; MULTIVALENT LIGANDS;
D O I
10.1021/cb300119g
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthetic immunology, the development of synthetic systems capable of modulating and/or manipulating immunological functions, represents an emerging field of research with manifold possibilities. One focus of this area has been to create low molecular weight synthetic species, called antibody-recruiting molecules (ARMs), which are capable of enhancing antibody binding to disease-relevant cells or viruses, thus leading to their immune-mediated clearance. This article provides a thorough discussion of contributions in this area, beginning with the history of small-molecule-based technologies for modulating antibody recognition, followed by a systematic review of the various applications of ARM-based strategies. Thus, we describe ARMs capable of targeting cancer, bacteria, and viral pathogens, along with some of the scientific discoveries that have resulted from their development. Research in this area underscores the many exciting possibilities at the interface of organic chemistry and immunobiology and is positioned to advance both basic and clinical science in the years to come.
引用
收藏
页码:1139 / 1151
页数:13
相关论文
共 179 条
[1]   Targeted cancer therapies [J].
Aggarwal, Saurabh .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) :427-428
[2]   What's fueling the biotech engine-2008 [J].
Aggarwal, Saurabh .
NATURE BIOTECHNOLOGY, 2009, 27 (11) :987-993
[3]   Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumors by dendritic cells [J].
Akiyama, K ;
Ebihara, S ;
Yada, A ;
Matsumura, K ;
Aiba, S ;
Nukiwa, T ;
Takai, T .
JOURNAL OF IMMUNOLOGY, 2003, 170 (04) :1641-1648
[4]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[5]   Antibody-drug conjugates: targeted drug delivery for cancer [J].
Alley, Stephen C. ;
Okeley, Nicole M. ;
Senter, Peter D. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) :529-537
[6]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[7]  
2-Z
[8]  
[Anonymous], 2012, FDA approved drug products
[9]  
[Anonymous], ANT DRUGS TECHN GLOB
[10]  
[Anonymous], 2 4 DIN CASRN 51 28